Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZOMEDICA CORP.

(ZOM)
  Report
Delayed Nyse  -  04:00:00 2023-03-21 pm EDT
0.2127 USD   +4.73%
03/20Zomedica Appoints New Chief Financial Officer
AQ
03/17Zomedica Corp. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
03/17Zomedica Pharmaceuticals CFO to Retire, Replacement Appointed
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zomedica Corp. Appoints Peter L. Donato as Its Chief Financial Officer

03/17/2023 | 06:30am EDT

Zomedica Corp. announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller.

Prior to joining Zomedica, Mr. Donato had a successful consulting practice specializing in public company readiness and was the Chief Financial Officer of Standard Bariatrics, a surgical company specializing in obesity surgery which was acquired by Teleflex in September of 2022. Mr. Donato has extensive experience with initial public offerings, business development and capital fund raising. Mr. Donato graduated from the Ohio State University, magna cum laude, with a BSBA in accounting and an MBA from the University of Akron, College of Business Administration.

Mr. Donato succeeds Ann Marie Cotter, who served as Zomedica's Vice President of Finance from August 2018 until October 2020, and subsequently as Chief Financial Officer. She is retiring to pursue personal interests.


© S&P Capital IQ 2023
All news about ZOMEDICA CORP.
03/20Zomedica Appoints New Chief Financial Officer
AQ
03/17Zomedica Corp. : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
03/17Zomedica Pharmaceuticals CFO to Retire, Replacement Appointed
MT
03/17Zomedica Corp. Appoints Peter L. Donato as Its Chief Financial Officer
CI
03/15Zomedica Corp. : Results of Operations and Financial Condition (form 8-K)
AQ
03/15ZOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and Results..
AQ
03/15Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
03/15Transcript : Zomedica Corp., Q4 2022 Earnings Call, Mar 15, 2023
CI
02/10Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022
AQ
02/09Zomedica Corp. Provides Earnings Guidance for the Fourth Quarter and Year Ended 2022
CI
More news
Analyst Recommendations on ZOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2023 - - -
Net income 2023 2,60 M - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 208 M 208 M -
Capi. / Sales 2023 -
Capi. / Sales 2024 -
Nbr of Employees 85
Free-Float 98,5%
Chart ZOMEDICA CORP.
Duration : Period :
Zomedica Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOMEDICA CORP.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
EPS Revisions
Managers and Directors
Larry C. Heaton Chief Executive Officer
Ann Marie Cotter Chief Financial Officer
Jeffrey M. Rowe Chairman
Ashley Wood Director-Research and Development
Evan Saint Peter Vice President-Technology Innovation
Sector and Competitors
1st jan.Capi. (M$)
ZOMEDICA CORP.24.60%199
MODERNA, INC.-13.97%59 595
LONZA GROUP AG17.46%42 649
SEAGEN INC.55.95%37 499
IQVIA HOLDINGS INC.-6.38%35 623
ALNYLAM PHARMACEUTICALS, INC.-21.09%23 277